Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
LPAR1
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "LPAR1" in MCE Product Catalog:
Referencia número: HY-162267
No. CAS: 3032275-33-2
Target:
Áreas de investigación:
LPAR1 antagonist 1 (compound 18) is a potent, oral active and selective LPAR1 antagonist with the IC50 of 3.3 nM. LPAR1 antagonist 1 can be used for study of fibrosis [1].
Referencia número: HY-159983
No. CAS: 2750508-72-4
Target:
Áreas de investigación:
GS-2278 is an LPAR1 (lysophosphatidic acid receptor 1) antagonist with potential for research in idiopathic pulmonary fibrosis (IPF) [1].
Referencia número: HY-160661
No. CAS: 1664336-46-2
Target:
Áreas de investigación:
LPAR1 antagonist 2 (example 76) is an LPAR1 antagonist with an average IC50 of 130 nM [1].
Referencia número: HY-RS07746
Target:
Áreas de investigación:
LPAR1 Human Pre-designed siRNA Set A contains three designed siRNAs for LPAR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Referencia número: HY-RS07747
Target:
Áreas de investigación:
Lpar1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lpar1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Referencia número: HY-RS07748
Target:
Áreas de investigación:
Lpar1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Lpar1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Referencia número: HY-171806
No. CAS: 1257213-96-9
Target:
Áreas de investigación:
BMT-136088 is a LPAR1 antagonist [1]. 11C-BMT-136088 can be used as a positron emission tomography (PET) radioligand to quantify specific binding to LPA1 in lung.
Referencia número: HY-149018
No. CAS: 2969213-59-8
Target:
Áreas de investigación:
ATX inhibitor 22 is a novel inhibitor of ATX (autotaxin) with IC50 of 218 nM but lost its inhibitory activity of LPAR1 [1].
Referencia número: HY-120282
No. CAS: 1802079-45-3
Target:
Áreas de investigación:
ONO-9910539 is a lysophosphatidic acid receptor 1 (LPAR1) antagonist. ONO-9910539 is applicable to the research of idiopathic pulmonary fibrosis [1].
Referencia número: HY-184986
No. CAS: 2901868-37-7
Áreas de investigación:
PIPE-791 is an orally active, blood-brain barrier-permeable selective antagonist of LPAR1. PIPE-791 inhibits LPA-induced calcium mobilization, collagen expression, histamine release, and the activation of fibroblasts, microglia and macrophages. PIPE-791 induces oligodendrocyte precursor cell differentiation, myelination and remyelination, and increases the number of microglia in the retina of normotensive rats. PIPE-791 protects mature oligodendrocytes from cytokine-induced death, reduces the levels of pulmonary fibrosis markers and alleviates neuroinflammation in preclinical models. PIPE-791 can be used in the research of glaucoma, neuroinflammatory diseases, chronic osteoarthritis pain, idiopathic pulmonary fibrosis and multiple sclerosis [1] .
Referencia número: HY-181931
No. CAS: 3058084-21-9
Áreas de investigación:
Autotaxin-IN-8 (Compound 14E) is an orally active Autotaxin inhibitor with an IC50 of 14.2 nM against hAutotaxin. Autotaxin-IN-8 inhibits Autotaxin activity, MAPK activation, LPAR1 and p-ERK1/2. Autotaxin-IN-8 reduces the phosphorylation levels of JNK and p38. Autotaxin-IN-8 decreases collagen deposition in a mouse model of pulmonary fibrosis. Autotaxin-IN-8 can be used in research related to pulmonary fibrosis [1].
Referencia número: HY-182787
No. CAS: 3057457-78-7
Target:
Áreas de investigación:
LPA1 receptor antagonist-7 is a LPA1 antagonist. LPA1 receptor antagonist-7 blocks downstream signaling pathways mediated by LPA1. LPA1 receptor antagonist-7 inhibits LPA-induced migration and invasion of cancer cells. LPA1 receptor antagonist-7 can be used for the research of triple-negative breast cancer [1].
Referencia número: HY-183657
Target:
Áreas de investigación:
GPR3 inverse agonist-1 is a GPR3 inverse agonist with low micromolar potency in conformational analysis. GPR3 inverse agonist-1 inhibits GPR3-dependent Gs activity in HEK293A cells with an EC50 of 250 nM, and exhibits an EC50 of 2 μM in cAMP assays. GPR3 inverse agonist-1 induces concentration-dependent changes in BRET signals in GPR3 conformational biosensors (EC50 = 5 μM), reduces basal Gs activity downstream of GPR3, and competes for binding sites with the GPR3 agonist DPI (HY-100965). GPR3 inverse agonist-1 can be used in research related to Alzheimer's disease [1].
Referencia número: HY-183657A
Target:
Áreas de investigación:
GPR3 inverse agonist-1 TFA is a GPR3 inverse agonist with low micromolar potency in conformational analysis. GPR3 inverse agonist-1 TFA inhibits GPR3-dependent Gs activity in HEK293A cells with an EC50 of 250 nM, and exhibits an EC50 of 2 μM in cAMP assays. GPR3 inverse agonist-1 TFA induces concentration-dependent BRET signal changes in GPR3 conformational biosensors (EC50 = 5 μM), reduces basal Gs activity downstream of GPR3, competes for binding sites with the GPR3 agonist DPI (HY-100965). GPR3 inverse agonist-1 TFA can be used in research related to Alzheimer's disease [1].
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
